Research Article

lymphocyte ratio, pan-immune-inflammation value and systemic immune-inflammation index for the efficacy of immunotherapy in patients with advanced gastric cancer

Department of Integrated Traditional Chinese & Western Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, 361015, People's Republic of China

Xiamen Clinical Research Center for Cancer Therapy, Xiamen, Fujian, 361015, People's Republic of China

‡Authors contributed equally

Search for more papers by this author

Xiuping Zhang‡

Department of Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, 361015, People's Republic of China

Xiamen Clinical Research Center for Cancer Therapy, Xiamen, Fujian, 361015, People's Republic of China

‡Authors contributed equally

Search for more papers by this author

Feng Shen

Department of Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, 361015, People's Republic of China

Xiamen Clinical Research Center for Cancer Therapy, Xiamen, Fujian, 361015, People's Republic of China

Search for more papers by this author

Jun Ma

*Author for correspondence: Tel.: +86 592 356 9607;

E-mail Address: ma.jun@zs-hospital.sh.cn

Department of Integrated Traditional Chinese & Western Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, 361015, People's Republic of China

Xiamen Clinical Research Center for Cancer Therapy, Xiamen, Fujian, 361015, People's Republic of China

Search for more papers by this author

Zhiyong Li

**Author for correspondence: Tel.: +86 592 356 9607;

E-mail Address: li.zhiyong@zsxmhospital.com

Department of Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, 361015, People's Republic of China

Xiamen Clinical Research Center for Cancer Therapy, Xiamen, Fujian, 361015, People's Republic of China

Search for more papers by this author

Published Online:5 Apr 2024https://doi.org/10.2217/imt-2024-0031

View article

Abstract

Aim: The study aimed to assess the value of pretreatment peripheral blood neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), pan-immune-inflammation value (PIV) and systemic immune-inflammation index (SII) for predicting immunotherapy prognosis and efficacy in advanced gastric cancer (GC). Methods: A total of 84 advanced GC patients received immunotherapy were retrospectively collected. The optimal cut-off values were determined by receiver operating characteristic curves. The univariate and multivariate analysis investigated the effects of NLR, PLR, PIV and SII on patients prognosis. Results: NLR, PLR, PIV and SII had predictive value of efficacy. NLR ≥3.65 was an independent risk factor for worse outcomes. Conclusion: NLR, PLR, PIV and SII have predictive value of efficacy and NLR ≥3.65 suggests a poor prognosis following immunotherapy in advanced GC.

Plain language summary

Immunotherapy can make gastric cancer patients live longer. However, not all patients live longer. We need simple, inexpensive and effective indicators to find patients who can live longer with immunotherapy. Routine blood test is common in our daily lives. Previous studies reported that some indicators in routine blood test can predict the prognosis and efficacy of surgery in gastric cancer patients. But it is not clear in immunotherapy for advanced gastric cancer patients. In our trial, we found that some indicators in routine blood test can help predict the effect of immunotherapy in patients with advanced gastric cancer and screen which patients will live longer with immunotherapy.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660 • Details the incidence and mortality rates of gastric cancer worldwide and provides a reference for the prevention and treatment of gastric cancer.
MedlineGoogle Scholar
2. Arnold M, Abnet CC, Neale RE et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 2020;159:335–349.e15. doi: 10.1053/j.gastro.2020.02.068
MedlineGoogle Scholar
3. Wang FH, Zhang XT, Li YF et al. The Chinese Society of Clinical Oncology (CSCO), Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun. (Lond). 2021;41:747–795. doi: 10.1002/cac2.12193
MedlineGoogle Scholar
4. Allemani C, Matsuda T, Di Carlo V et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1023–1075. doi: 10.1016/S0140-6736(17)33326-3
MedlineGoogle Scholar
5. Jim MA, Pinheiro PS, Carreira H et al. Stomach cancer survival in the United States by race and stage (2001–2009): findings from the CONCORD-2 study. Cancer 2017;123(Suppl. 24):4994–5013. doi: 10.1002/cncr.30881
MedlineGoogle Scholar
6. Li Y, Feng A, Zheng S et al. Recent estimates and predictions of 5-year survival in patients with gastric cancer: a model-based period analysis. Cancer Control. 2022;29:10732748221099227. doi: 10.1177/10732748221099227
Google Scholar
7. Li J, Cui T, Huang Z et al. Analysis of risk factors for lymph node metastasis and prognosis study in patients with early gastric cancer: a SEER data-based study. Front. Oncol. 2023;13:1062142. doi: 10.3389/fonc.2023.1062142
Medline CASGoogle Scholar
8. Smyth EC, Nilsson M, Grabsch HI et al. Gastric cancer. Lancet 2020;396:635–648. doi: 10.1016/S0140-6736(20)31288-5
Medline CASGoogle Scholar
9. Shitara K, Van Cutsem E, Bang YJ et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 Phase III randomized clinical trial. JAMA Oncol. 2020;6:1571–1580. doi: 10.1001/jamaoncol.2020.3370 •• Compared with chemotherapy, the PD1 inhibitor pembrolizumab significantly prolonged overall survival (OS) in patients with gastric cancer. The study represented a breakthrough in the field of gastric cancer treatment and rewritten the guidelines for gastric cancer treatment.
MedlineGoogle Scholar
10. Ajani JA, D'Amico TA, Bentrem DJ et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2022;20:167–192. doi: 10.6004/jnccn.2022.0008 • The NCCN Guidelines are internationally recognized oncology treatment guidelines that systematically analyze the latest research in the field of oncology and update all types of treatment options and levels of evidence and they are updated very quickly to help physicians quickly access authoritative and up-to-date treatment options.
Medline CASGoogle Scholar
11. Lordick F, Carneiro F, Cascinu S et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2022;33:1005–1020. doi: 10.1016/j.annonc.2022.07.004
Medline CASGoogle Scholar
12. Kim TH, Kim IH, Kang SJ et al. Korean Practice Guidelines for Gastric Cancer 2022: an evidence-based, multidisciplinary approach. J. Gastric Cancer 2023;23:3–106. doi: 10.5230/jgc.2023.23.e11
MedlineGoogle Scholar
13. Fuchs CS, Doi T, Jang RW et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase II Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4:e180013. doi: 10.1001/jamaoncol.2018.0013
MedlineGoogle Scholar
14. Bang YJ, Kang YK, Catenacci DV et al. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer 2019;22:828–837. doi: 10.1007/s10120-018-00909-5
Medline CASGoogle Scholar
15. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017;541:321–330. doi: 10.1038/nature21349
Medline CASGoogle Scholar
16. Janjigian YY, Shitara K, Moehler M et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, Phase III trial. Lancet 2021;398:27–40. doi: 10.1016/S0140-6736(21)00797-2
Medline CASGoogle Scholar
17. Chao J, Fuchs CS, Shitara K et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7:895–902. doi: 10.1001/jamaoncol.2021.0275
MedlineGoogle Scholar
18. Zhang Y, Yang Y, Chen Y et al. PD-L1: biological mechanism, function, and immunotherapy in gastric cancer. Front. Immunol. 2022;13:1060497. doi: 10.3389/fimmu.2022.1060497 •• This review provided information on the endogenous and exogenous regulatory mechanisms of PD-L1 and its biological functions combined with current clinical trials of PD-L1/PD-1 inhibitors in gastric cancer and introduced the biomarkers of the potential efficacy of immunotherapy in gastric cancer.
Medline CASGoogle Scholar
19. Cheng Y, Bu D, Zhang Q et al. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer. J. Adv. Res. 2023;51:121–134. doi: 10.1016/j.jare.2022.10.019
Medline CASGoogle Scholar
20. Yang Y, Shi Z, Bai R et al. Heterogeneity of MSI-H gastric cancer identifies a subtype with worse survival. J. Med. Genet. 2021;58:12–19. doi: 10.1136/jmedgenet-2019-106609
Medline CASGoogle Scholar
21. Wang M, Ran X, Leung W et al. ATR inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy. Genes Dev. 2023;37:929–943. doi: 10.1101/gad.351084.123
Medline CASGoogle Scholar
22. Yeong J, Lum H, Teo CB et al. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer. 2022;25:741–750. doi: 10.1007/s10120-022-01301-0
Medline CASGoogle Scholar
23. Tsao MS, Kerr KM, Kockx M et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint Phase II Project. J. Thorac. Oncol. 2018;13:1302–1311. doi: 10.1016/j.jtho.2018.05.013
MedlineGoogle Scholar
24. Paver EC, Cooper WA, Colebatch AJ et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumors: a guide to immunohistochemistry implementation and interpretation. Pathology 2021;53:141–156. doi: 10.1016/j.pathol.2020.10.007
Medline CASGoogle Scholar
25. Xu X, Chen J, Li W et al. Immunology and immunotherapy in gastric cancer. Clin. Exp. Med. 2023;23:3189–3204. doi: 10.1007/s10238-023-01104-2
MedlineGoogle Scholar
26. Hara K, Aoyama T, Yamada T et al. The prognostic value of the perioperative systemic inflammation score for patients with advanced gastric cancer. Anticancer Res. 2020;40:1503–1512. doi: 10.21873/anticanres.14095
MedlineGoogle Scholar
27. Zhang J, Zhang L, Duan S et al. Single and combined use of the platelet-lymphocyte ratio, neutrophil-lymphocyte ratio, and systemic immune-inflammation index in gastric cancer diagnosis. Front. Oncol. 2023;13:1143154. doi: 10.3389/fonc.2023.1143154
MedlineGoogle Scholar
28. Ock CY, Nam AR, Lee J et al. Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. Gastric Cancer 2017;20:254–262. doi: 10.1007/s10120-016-0613-5
Medline CASGoogle Scholar
29. Mosca M, Nigro MC, Pagani R et al. Neutrophil-to-lymphocyte ratio (NLR) in NSCLC, gastrointestinal, and other solid tumors: immunotherapy and beyond. Biomolecules 2023;13:1803. doi: 10.3390/biom13121803
Medline CASGoogle Scholar
30. Qiu Y, Zhang Z, Chen Y. Prognostic value of pretreatment systemic immune-inflammation index in gastric cancer: a meta-analysis. Front. Oncol. 2021;11:537140. doi: 10.3389/fonc.2021.537140
MedlineGoogle Scholar
31. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009;45:228–247. doi: 10.1016/j.ejca.2008.10.026
Medline CASGoogle Scholar
32. Montagne JM, Jaffee EM, Fertig EJ. Multiomics empowers predictive pancreatic cancer immunotherapy. J. Immunol. 2023;210:859–868. doi: 10.4049/jimmunol.2200660
Medline CASGoogle Scholar
33. Nie Y, Zhao W, Lu L et al. Predictive biomarkers and new developments of immunotherapy in gastric cancer: a 2023 update. Am. J. Cancer Res. 2023;13:3169–3184
Medline CASGoogle Scholar
34. Ravindranathan D, Master VA, Bilen MA. Inflammatory markers in cancer immunotherapy. Biology (Basel). 2021;10:325. doi: 10.3390/biology10040325
MedlineGoogle Scholar
35. Sun D, Liu J, Zhang L. Establishment of tumor immune microenvironment classification model to select patients sensitive to immunotherapy. J. Thorac. Oncol. 2023;18:e111–e112. doi: 10.1016/j.jtho.2023.07.003 •• This article is inspiring and groundbreaking in exploring immunotherapy predictors from the perspective of the immune microenvironment by building an immune microenvironment classification model to screen patients sensitive to immunotherapy.
Medline CASGoogle Scholar
36. Adegoke NA, Gide TN, Mao Y et al. Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies. J. Immunother. Cancer 2023;11:e007144. doi: 10.1136/jitc-2023-007144
MedlineGoogle Scholar
37. Belkouchi Y, Nebot-Bral L, Lawrance L et al. Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume. Front. Oncol. 2022;12:982790. doi: 10.3389/fonc.2022.982790
Medline CASGoogle Scholar
38. Zhou K, Cao J, Lin H et al. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: a systematic review and meta-analysis. Front. Oncol. 2022;12:962173. doi: 10.3389/fonc.2022.962173
MedlineGoogle Scholar
39. Wu Y, Jiang M, Qin Y et al. Single and combined use of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and carcinoembryonic antigen in diagnosing gastric cancer. Clin. Chim. Acta 2018;481:20–24. doi: 10.1016/j.cca.2018.02.027
Medline CASGoogle Scholar
40. Zhang LX, Wei ZJ, Xu AM et al. Can the neutrophil-lymphocyte ratio and platelet-lymphocyte ratio be beneficial in predicting lymph node metastasis and promising prognostic markers of gastric cancer patients? Tumor maker retrospective study. Int. J. Surg. 2018;56:320–327. doi: 10.1016/j.ijsu.2018.06.037
MedlineGoogle Scholar
41. Shimada H, Takiguchi N, Kainuma O et al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 2010;13:170–176. doi: 10.1007/s10120-010-0554-3
MedlineGoogle Scholar
42. Zhang S, Xia K, Chang Y et al. LRP2 and DOCK8 are potential antigens for mRNA vaccine development in immunologically ‘cold’ KIRC tumors. Vaccines (Basel). 2023;11:396. doi: 10.3390/vaccines11020396
Google Scholar
43. Pennel K, Park JH, McMillan DC et al. Signal interaction between the tumor and inflammatory cells in patients with gastrointestinal cancer: implications for treatment. Cell. Signal. 2019;54:81–90. doi: 10.1016/j.cellsig.2018.11.013
Medline CASGoogle Scholar
44. Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics 2021;11:5365–5386. doi: 10.7150/thno.58390
Medline CASGoogle Scholar
45. White K, Connor K, Meylan M et al. Identification, validation and biological characterisation of novel glioblastoma tumor microenvironment subtypes: implications for precision immunotherapy. Ann. Oncol. 2023;34:300–314. doi: 10.1016/j.annonc.2022.11.008
Medline CASGoogle Scholar
46. Duan Q, Zhang H, Zheng J et al. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer 2020;6:605–618. doi: 10.1016/j.trecan.2020.02.022
Medline CASGoogle Scholar
47. Ortiz-Muñoz G, Brown M, Carbone CB et al. In situ tumor arrays reveal early environmental control of cancer immunity. Nature 2023;618:827–833. doi: 10.1038/s41586-023-06132-2
Medline CASGoogle Scholar
48. Sun R, Limkin EJ, Vakalopoulou M et al. A radiomics approach to assess tumor-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19:1180–1191. doi: 10.1016/S1470-2045(18)30413-3
Medline CASGoogle Scholar
49. Guo W, Cai S, Zhang F et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer. Thorac. Cancer 2019;10:761–768. doi: 10.1111/1759-7714.12995
Medline CASGoogle Scholar
50. Huang H, Liu Q, Zhu L et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci. Rep. 2019;9:3284. doi: 10.1038/s41598-019-39150-0
MedlineGoogle Scholar
51. Xue R, Zhang Q, Cao Q et al. Liver tumor immune microenvironment subtypes and neutrophil heterogeneity. Nature 2022;612:141–147. doi: 10.1038/s41586-022-05400-x
Medline CASGoogle Scholar
52. Faria A, Andrade SS, Peppelenbosch MP et al. Platelets in aging and cancer-“double-edged sword”. Cancer Metastas. Rev. 2020;39:1205–1221. doi: 10.1007/s10555-020-09926-2
MedlineGoogle Scholar
53. Hirahara N, Matsubara T, Fujii Y et al. Comparison of the prognostic value of immunoinflammation-based biomarkers in patients with gastric cancer. Oncotarget 2020;11:2625–2635. doi: 10.18632/oncotarget.27653
MedlineGoogle Scholar
54. Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J. Hematol. Oncol. 2017;10:58. doi: 10.1186/s13045-017-0430-2
Google Scholar

Ahead of Print

Supplemental Materials

Metrics

Downloaded 37 times

History

Received 29 January 2024

Accepted 19 March 2024

Published online 5 April 2024

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/imt-2024-0031

Author contributions

All authors contributed to the method conception and program design of this study. The research data collection, organization and statistical analysis were performed by M Fu, Z Li and X Zhang. The research data and statistical results proofreading was done by J Ma and F Shen. The first draft of the manuscript was written by M Fu and X Zhang. The revision of the manuscript was done by M Fu and Z Li. All the authors participated in the final proofreading of the manuscript and confirmed that there was no relevant conflict of interest.

Financial disclosure

This work was supported by the Fujian Provincial Health Technology Project under Grant 2021QNB020; and Xiamen Medical and Health Guidance Project under Grant 3502Z20214ZD1075 and 3502Z20224ZD1086. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. This study was approved by Ethics Committee of Zhongshan Hospital, Fudan University (Xiamen Branch) (No. B2023-136).

Data availability statement

The data that support the findings of this study are available from the corresponding author MD F upon reasonable request.

PDF download